Publications by authors named "Thomas Lieber"

Claim this Profile
N
Natural language processing for automated triage and prioritization of individual case safety reports for case-by-case assessment.
Thomas Lieber, Helen R Gosselt, Pelle C Kools, Okko C Kruijssen, Stijn N C Van Lierop

Front Drug Saf Regul· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of Perceived Adverse Events After COVID-19 Vaccination Between Pregnant and NonPregnant Women Using Two Cohort Studies in the Netherlands.
Petra J Woestenberg, Annika W Terpstra, Florence van Hunsel, Thomas Lieber, Veronique Y F Maas

Birth Defects Res· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
What is the Safety of COVID-19 Vaccines in Immunocompromised Patients? Results from the European "Covid Vaccine Monitor" Active Surveillance Study.
Chiara Bellitto, Nicoletta Luxi, Francesco Ciccimarra, Luca L'Abbate, Monika Raethke, Thomas Lieber

Drug Saf· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of COVID-19 Vaccines among People with History of Allergy: A European Active Surveillance Study.
Nicoletta Luxi, Francesco Ciccimarra, Chiara Bellitto, Monika Raethke, Florence van Hunsel, Thomas Lieber

Vaccines (Basel)· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Frequency and timing of adverse reactions to COVID-19 vaccines; A multi-country cohort event monitoring study.
Monika Raethke, Florence van Hunsel, Nicoletta Luxi, Thomas Lieber, Chiara Bellitto

Vaccine· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety Monitoring of COVID-19 Vaccines in Persons with Prior SARS-CoV-2 Infection: A European Multi-Country Study.
Francesco Ciccimarra, Nicoletta Luxi, Chiara Bellitto, Luca L'Abbate, Monika Raethke, Thomas Lieber

Vaccines (Basel)· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sex-disaggregated outcomes of adverse events after COVID-19 vaccination: A Dutch cohort study and review of the literature.
Janneke W Duijster, Thomas Lieber, Silvia Pacelli, Leontine Van Balveren, Loes S Ruijs

Front Immunol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a multivariate prediction model to identify individual case safety reports which require clinical review.
Helen R Gosselt, Elizabeth A Bazelmans, Thomas Lieber, Florence P A M van Hunsel, Linda Härmark

Pharmacoepidemiol Drug Saf· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Humoral and cellular SARS-CoV-2 vaccine responses in patients with giant cell arteritis and polymyalgia rheumatica.
Yannick van Sleen, Kornelis S M van der Geest, Rosanne D Reitsema, Idil Esen, Janneke H Terpstra, Thomas Lieber

RMD Open· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Numerical Investigations on Thermal Forming Limit Testing with Local Inductive Heating for Hot Forming of AA7075.
Franz Reuther, Thomas Lieber, Jürgen Heidrich, Verena Kräusel

Materials (Basel)· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis